Menu
Amprion’s owned or exclusively-licensed alpha-synuclein portfolio is particularly extensive. The portfolio currently includes multiple allowed and/or issued patents in the United States, EU, Japan, UK, Korea, Singapore, Australia, Israel, Canada, and Mexico, with applications pending in India, China, Hong Kong, and Brazil. Amprion also has an issued US patent and pending applications worldwide directed to Amprion’s proprietary alpha-synuclein SAA substrate plus other key components needed for robust, reliable and reproducible performance of the technology.
“Neurodegenerative diseases affect individuals differently. For instance, ten patients can have ten different biomarker profiles. In addition, symptoms often overlap, leading to diagnostic challenges.
The SAAmplify-ɑSYN Test offers physicians a molecular tool to greatly improve diagnostic accuracy. Our goal is to develop precision medicine through biomarker testing.”
A pioneer in the science of detecting misfolded proteins, Amprion advances the diagnosis of brain disorders. Our SAAmplify™-ɑSYN Test aids physicians in diagnosing Parkinson’s, Lewy body dementia, and Alzheimer’s with Lewy body variant. We plan to launch more biomarker tests in the future.
